These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22322320)

  • 21. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Ma BBY; Kam MKM; Leung SF; Hui EP; King AD; Chan SL; Mo F; Loong H; Yu BKH; Ahuja A; Chan ATC
    Ann Oncol; 2012 May; 23(5):1287-1292. PubMed ID: 21948811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
    Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
    Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.
    Fury MG; Lee NY; Sherman E; Lisa D; Kelly K; Lipson B; Carlson D; Stambuk H; Haque S; Shen R; Kraus D; Shah J; Pfister DG
    Cancer; 2012 Oct; 118(20):5008-14. PubMed ID: 22415650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
    Vokes EE; Haraf DJ; Brockstein BE; Weichselbaum RR
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):70-6. PubMed ID: 10210543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
    Vokes EE; Haraf DJ; Mick R; McEvilly JM; Weichselbaum RR
    J Clin Oncol; 1994 Nov; 12(11):2351-9. PubMed ID: 7525886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
    Seiwert TY; Haraf DJ; Cohen EE; Stenson K; Witt ME; Dekker A; Kocherginsky M; Weichselbaum RR; Chen HX; Vokes EE
    J Clin Oncol; 2008 Apr; 26(10):1732-41. PubMed ID: 18375903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer.
    Kim B; Dillman RO; Chen P; Hafer R; Cox C; Barth N; Carroll RM; VanderMolen L; Nguyen M; Huang J; Minion A; Plunkett M; Mackintosh R
    Am J Otolaryngol; 2012; 33(1):93-7. PubMed ID: 21524816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer.
    Argiris A; Heron DE; Smith RP; Kim S; Gibson MK; Lai SY; Branstetter BF; Posluszny DM; Wang L; Seethala RR; Dacic S; Gooding W; Grandis JR; Johnson JT; Ferris RL
    J Clin Oncol; 2010 Dec; 28(36):5294-300. PubMed ID: 21079141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
    Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
    Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
    Vokes EE; Stenson K; Rosen FR; Kies MS; Rademaker AW; Witt ME; Brockstein BE; List MA; Fung BB; Portugal L; Mittal BB; Pelzer H; Weichselbaum RR; Haraf DJ
    J Clin Oncol; 2003 Jan; 21(2):320-6. PubMed ID: 12525525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
    Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C
    Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).
    Shapiro LQ; Sherman EJ; Riaz N; Setton J; Koutcher L; Zhang Z; Shi W; Fury MG; Wolden SL; Pfister DG; Morris L; Lee N
    Oral Oncol; 2014 Oct; 50(10):947-55. PubMed ID: 25132089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
    Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
    Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
    Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
    Pederson AW; Salama JK; Witt ME; Stenson KM; Blair EA; Vokes EE; Haraf DJ
    Am J Clin Oncol; 2011 Aug; 34(4):356-61. PubMed ID: 21633289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.